In a recent study published in the journal Immunity, researchers reviewed the T cell response in cancer and autoimmunity to propose strategies for more effective immunotherapies.
Review: Learning from the nexus of autoimmunity and cancer. Image Credit: Meletios Verras / Shutterstock.
“It doesn’t have just a static function. It has a bank of sensors that measure chemicals in the blood and feeds that information back to the device,” Kurtz says.
Other startups are getting in on the game. Nephria Bio, a spinout from the South Korean-based EOFlow, is working to develop a wearable dialysis device, akin to an insulin pump, that uses miniature cartridges with nanomaterial filters to clean blood (Harhay is a scientific advisor to Nephria). Ian Welsford, Nephria’s co-founder and CTO, says that the device’s design means that it can also be used to treat acute kidney injuries in resource-limited settings. These potentials have garnered interest and investment in artificial kidneys from the U.S. Department of Defense.
For his part, Burton is most interested in an implantable device, as that would give him the most freedom. Even having a regular outpatient procedure to change batteries or filters would be a minor inconvenience to him.
A single drop of blood from a finger prick. A simple electronic chip. And a smartphone readout of test results that could diagnose a Covid-19 infections or others like HIV or Lyme disease.
It sounds a bit like science fiction, like the beginnings of the medical tricorder used by doctors on Star Trek. Yet researchers at Georgia Tech and Emory University have taken the first step to showing it can be done, and they’ve published their results in the journal Small.
Postdoctoral fellow Neda Rafat and Assistant Professor Aniruddh Sarkar created a small chip that harnesses the fundamental chemistry of the gold-standard lab method but uses electrical conductivity instead of optics to detect antibodies and indicate infection.
National Institutes of Health researchers have developed and released an innovative software tool to assemble truly complete (i.e., gapless) genome sequences from a variety of species.
This software, called Verkko, which means “network” in Finnish, makes the process of assembling complete genome sequences more affordable and accessible. A description of the new software was published today in Nature Biotechnology.
Verkko grew from assembling the first gapless human genome sequence, which was finished last year by the Telomere-to-Telomere (T2T) consortium, a collaborative project funded by the National Human Genome Research Institute (NHGRI), part of NIH.
It acted with rudimentary intelligence, learning, evolving and communicating with itself to grow more powerful.
A new model by a team of researchers led by Penn State and inspired by Crichton’s novel describes how biological or technical systems form complex structures equipped with signal-processing capabilities that allow the systems to respond to stimulus and perform functional tasks without external guidance.
“Basically, these little nanobots become self-organized and self-aware,” said Igor Aronson, Huck Chair Professor of Biomedical Engineering, Chemistry, and Mathematics at Penn State, explaining the plot of Crichton’s book. The novel inspired Aronson to study the emergence of collective motion among interacting, self-propelled agents. The research was recently published in Nature Communications.
Year 2020 face_with_colon_three
Frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) are two fatal and incurable neurodegenerative diseases linked by a shared genetic cause – a heterozygous hexanucleotide (GGGGCC) repeat expansion in a single allele of the C9orf72 gene. The goal of this work is to develop novel CRISPR based therapeutic gene editing technologies and test whether gene editing can reverse the cellular pathology caused by this repeat expansion in patient derived cells. The results of these studies will advance our use of CRISPR technologies for therapeutic editing in FTD/ALS, inform our understanding of the regulation of C9orf72 gene, and will be applicable to many other repeat expansion and single gene disorders.
AI automation is being deployed throughout the drug development pipeline, opening up the possibility of faster, cheaper pharmaceuticals.
For years, researchers have searched for the working principles of self-assembly that can build a cell (complex biological organism) as well as a crystal (far simpler inorganic material) in the same way.
Now, a team of scientists in Turkey has demonstrated the fundamental principles of a universal self-assembly process acting on a range of materials starting from a few atoms-large quantum dots up to nearly 100 trillion atoms-large human cells. Their method is highlighted in Nature Physics.
“To initiate self-assembly, either you force the system to deliver a specific outcome, or you use its inner dynamics to your advantage for universal outcomes. We followed the second approach,” says Dr. Serim Ilday of Bilkent University-UNAM, who lead the study.
Three years into the pandemic, the immune systems of the vast majority of humans have learnt to recognize SARS-CoV-2 through vaccination, infection or, in many cases, both. But just how quickly do these types of immunity fade?
New evidence suggests that ‘hybrid’ immunity, the result of both vaccination and a bout of COVID-19, can provide partial protection against reinfection for at least eight months1. It also offers greater than 95% protection against severe disease or hospitalization for between six months and a year after an infection or vaccination, according to estimates from a meta-analysis2. Immunity acquired by booster vaccination alone seems to fade somewhat faster.
But the durability of immunity is much more complex than the numbers suggest. How long the immune system can fend off SARS-CoV-2 infection depends not only on how much immunity wanes over time but also on how well immune cells recognize their target. “And that has more to do with the virus and how much it mutates,” says Deepta Bhattacharya, an immunologist at the University of Arizona College of Medicine in Tucson. If a new variant finds ways to escape the existing immune response, then even a recent infection might not guarantee protection.
